WO2017045599A1 - 环己烷衍生物或其立体异构体或盐及其制备与应用 - Google Patents
环己烷衍生物或其立体异构体或盐及其制备与应用 Download PDFInfo
- Publication number
- WO2017045599A1 WO2017045599A1 PCT/CN2016/098953 CN2016098953W WO2017045599A1 WO 2017045599 A1 WO2017045599 A1 WO 2017045599A1 CN 2016098953 W CN2016098953 W CN 2016098953W WO 2017045599 A1 WO2017045599 A1 WO 2017045599A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- group
- ethyl
- acid
- trans
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/66—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/72—Benzo[c]thiophenes; Hydrogenated benzo[c]thiophenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the present invention relates to medicinal chemistry, in particular to cyclohexane compounds or stereoisomers or salts thereof, and in particular to cyclohexane derivatives of formula IB and formula I or stereoisomers or salts thereof, and their preparation and application.
- Patent WO 9967206 A1 describes the use of cyclohexane derivatives in the treatment of pain disorders, but does not publicly report their use in psychotic diseases, especially on the dopamine D 2 /D 3 receptor.
- Patent CN 1829703A describes the use of a cyclohexane derivative having a (thio)carbamoyl side chain in the regulation of a dopamine receptor disorder, wherein the D 2 /D 3 antagonist and 5 jointly developed by Forest Laboratories and Gedeon Richter -
- the HT 1A partial agonist, Cariprazine (RGH-188) has been completed in clinical trials for the treatment of schizophrenia and mania and depression.
- the chemical structure of the cariprazine is shown in the following formula.
- the affinity (Ki value) of the drug for the D 2 /D 3 receptor and 5-HT 1A is 0.72 nmol, 0.08 nmol and 3.42 nmol, respectively, for D 2 /D.
- the 3 receptor has certain selectivity, it is still not ideal, so it may cause the drug to have a low probability of clinically (approximately 5% probability at 3 mg dose) of sedation and the cause of extracorporeal reaction. Because these side effects are associated with excessive blockade of the D 2 receptor.
- the patent CN 103130737A has further structural modification of the cariprazine to achieve higher D 3 receptor selectivity.
- the technical problem to be solved by the present invention is to overcome the above-mentioned deficiencies, and to study and design to improve the structure of a cyclohexane derivative, and to provide a cyclohexane derivative or a stereoisomer thereof or a salt thereof as shown in Formula IB and Formula I, It has D 2 /D 3 antagonist action and serotonin absorption inhibition, as well as anti-schizophrenia, increases the broad spectrum of treatment for psychotic diseases, and reduces side effects.
- the cyclohexane derivative or a stereoisomer or salt thereof provided by the present invention has the structure shown in the following formula IB:
- the R group may be optionally substituted by one or more substituents selected from halogen, substituted or unsubstituted C 1 -C 6 alkyl;
- the halogen is selected from F, Cl, One or more of Br or I;
- the substituted or unsubstituted C 1 -C 6 alkyl group is selected from a substituted or unsubstituted C 1 -C 4 alkyl group, such as methyl, ethyl, propyl or Butyl
- the substituent is a halogen, such as one or more of F, Cl, Br or I
- the substituted C 1 -C 4 alkyl group is preferably a trifluoromethyl group.
- the cyclohexane derivative provided by the present invention or a stereoisomer or salt thereof, has the structure shown in the following formula I:
- the R group may be optionally substituted by one or more substituents selected from halogen, substituted or unsubstituted C 1 -C 6 alkyl;
- the halogen is selected from F, Cl, One or more of Br or I;
- the substituted or unsubstituted C 1 -C 6 alkyl group is selected from a substituted or unsubstituted C 1 -C 4 alkyl group, such as methyl, ethyl, propyl or Butyl
- the substituent is a halogen, such as one or more of F, Cl, Br or I
- the substituted C 1 -C 4 alkyl group is preferably a trifluoromethyl group.
- the stereoisomer of the cyclohexane derivative of the present invention is a cis stereoisomer or a trans stereoisomer, preferably a trans stereoisomer.
- the salt of the cyclohexane derivative of the present invention is formed from a cyclohexane derivative which is an organic acid or an inorganic acid, and the inorganic acid is selected from hydrochloric acid, sulfuric acid, nitric acid or phosphoric acid; From formic acid, acetic acid, oxalic acid malonic acid, maleic acid, fumaric acid, succinic acid or benzoic acid; and other physiologically acceptable salts.
- the cyclohexane derivative of the present invention or a stereoisomer or salt thereof is selected from the following compounds or salts thereof:
- Another object of the present invention is to provide a process for the preparation of the cyclohexane derivative, or a stereoisomer or salt thereof, which comprises the steps of:
- the molar ratio of the compound II to the compound III is 1-1.5:1, the reaction temperature is 0 ° C - 50 ° C, the acid binding agent is an organic basic substance or an inorganic basic substance; the organic basic substance is selected from the group consisting of three One or more of an amine, diisopropylethylamine or pyridine selected from one or more of sodium carbonate, potassium carbonate, sodium hydrogencarbonate or potassium hydrogencarbonate, the binding
- the molar ratio of acid agent (basic compound) to compound II is 1-1.5:1.
- the invention also provides a preparation method of the compound II, the method comprising the following steps:
- R and X are as defined above, and Pg is an amino protecting group selected from the group consisting of benzyl Bn, benzyl formate CBz or t-butoxycarbonyl Boc.
- Pg is an amino protecting group selected from the group consisting of benzyl Bn, benzyl formate CBz or t-butoxycarbonyl Boc.
- the compound of formula II may itself be cis or trans, or the compound of formula IB may be finally chromatographed or crystallized to obtain its cis stereoisomer.
- the coupling reaction is carried out under the palladium catalysis, in the presence of a strong base potassium t-butoxide, sodium t-butoxide, potassium carbonate or cesium carbonate, the reaction temperature is 50-150 ° C, the molar ratio of piperazine to bromine 1-5:1; or,
- the reducing agent is a boron compound such as sodium triacetoxyborohydride or sodium borohydride; the molar ratio of the intermediate IV to the 4-amino protected cyclohexaneacetaldehyde is 1-1.2:1; the boron compound and the intermediate The body IV molar ratio is 1-2:1;
- Pg is t-butoxycarbonyl Boc
- an acid deamination protecting group is added; the acid is an organic solution of hydrogen chloride or trifluoroacetic acid; or, when Pg is benzyl Bn or benzyl formate CBz, A palladium carbon hydrodeamination protecting group is used, and the hydrogenation pressure is from 0.1 to 1 MPa.
- a further object of the present invention is to provide use of the cyclohexane derivative or a stereoisomer or salt thereof for the preparation of a medicament for anti-neuropsychiatric diseases.
- the cyclohexane derivative or the stereoisomer or salt thereof according to the present invention is a drug-effect structure having potential action on dopamine D 3 receptor and has potential serotonin absorption according to the design principle of the compound pharmacodynamic structure fusion drug. Inhibition of the pharmacodynamic structure of the fusion, through the structural modification of the compound, preparation, in vitro activity test, in vivo anti-schizophrenia activity test, structure-activity relationship study and re-optimization of new compounds.
- the results of pharmacological studies indicate that the cyclohexane derivative of the present invention or a stereoisomer or salt thereof has a strong affinity for the D 3 receptor and serotonin, and has a weak affinity for the D 2 receptor, showing a pair D.
- the high selectivity of the 3 /D 2 receptor achieves unexpected results.
- the in vitro receptor binding assay showed that most of the compounds involved in the cyclohexane derivative or its stereoisomer or salt of the present invention have a strong affinity for the dopamine D 3 receptor and the 5-HT 1A receptor (Ki ⁇ 10 nmol).
- the in vivo anti-schizophrenia activity test showed that the cyclohexane derivative of the present invention or a stereoisomer or salt thereof has a strong anti-schizophrenia symptom.
- benzoheterocyclic fragment such as benzothiophene, benzisothiazole or benzisoxazole fragment in the structure of the cyclohexane derivative series compound is closely related (the corresponding fragment of the existing carilazide is 2, 3 chlorobenzene).
- the cyclohexane derivative of the present invention or a stereoisomer or salt thereof can be used for the preparation of a neuropsychiatric drug.
- the medicament according to the present invention means a pharmaceutical composition comprising the cyclohexane derivative or a stereoisomer or salt thereof as an active ingredient and a pharmaceutically acceptable adjuvant.
- the pharmaceutical composition of the present invention can be selected for any convenient mode of administration.
- oral, gastrointestinal, buccal, sublingual, nasal, rectal or transdermal administration It can be developed into different dosage forms such as solid dosage forms and liquid dosage forms such as suspensions, tablets, capsules.
- the composition in the form of a solid tablet may contain a filler, a lubricant, a binder, a disintegrator conventionally used in the formulation.
- the liquid preparation is a liquid carrier such as a water-soluble solvent such as water, ethanol or glycerin, or a water-insoluble solvent such as polyethylene glycol or a suspension or solution in an oil.
- the pharmaceutical composition of the present invention is a solid tablet comprising a cyclohexane derivative of the formula IB or the formula I or a stereoisomer or salt thereof as an active ingredient and a pharmaceutically acceptable adjuvant.
- the solid tablet consists of the following weight ratio components:
- the diluent is selected from the group consisting of starch, lactose or microcrystalline cellulose; the binder is selected from the group consisting of hydroxybenzylcellulose, hydroxypropylmethylcellulose or polyvinylpyrrolidone; the disintegrant is selected from hydroxyB Based on sodium starch or crospovidone, the lubricant is magnesium stearate.
- the present invention provides N'-[trans-4-[2-[4-(benzo[b]thiophene)-7-piperazinyl]ethyl]cyclohexyl]-N,N-dimethyl
- a base urea compound is used as a solid tablet composed of an active ingredient and a pharmaceutically acceptable adjuvant.
- the solid tablet consists of the following weight ratio components:
- the diluent is selected from the group consisting of starch, lactose or microcrystalline cellulose
- the binder is selected from the group consisting of hydroxybenzylcellulose, hydroxypropylmethylcellulose or polyvinylpyrrolidone
- the disintegrant is selected from sodium hydroxyethyl starch or Dividone
- the lubricant is magnesium stearate.
- the pharmaceutical composition of the present invention is a suspension comprising a cyclohexane derivative of the formula IB or the formula I or a stereoisomer or salt thereof as an active ingredient and a pharmaceutically acceptable adjuvant.
- the suspension consists of the following weight ratio components:
- the suspending agent is selected from the group consisting of xanthan gum or microcrystalline cellulose; the preservative is selected from sodium benzoate, methyl p-hydroxybenzoate or ethyl p-hydroxybenzoate, the diluent being selected from water or sorbitol;
- the buffering agent is a citrate;
- the cosolvent is selected from the group consisting of cyclodextrin, ethanol, propylene glycol or polyethylene glycol;
- the flavoring agent may be a sweetener (such as sugar, saccharin, etc.) well known to those skilled in the art;
- the agent may be a fat-soluble colorant or a water-soluble colorant such as carotene, Cocoa pigment, caramel color, etc.
- the present invention provides N'-[trans-4-[2-[4-(benzo[b]thiophene)-7-piperazinyl]ethyl]cyclohexyl]-N,N-dimethyl
- a base urea compound is used as a suspension of the active ingredient and a pharmaceutical excipient.
- the suspension consists of the following weight ratio components:
- the suspending agent is selected from the group consisting of xanthan gum or microcrystalline cellulose
- the preservative is selected from the group consisting of sodium benzoate, methyl p-hydroxybenzoate, ethyl p-hydroxybenzoate
- the diluent is selected from the group consisting of water, sorbitol
- the buffer is lemon.
- the acid salt, the co-solvent is selected from the group consisting of cyclodextrin, ethanol, propylene glycol or polyethylene glycol
- the flavoring agent may be a sweetener (such as sugar, saccharin, etc.) well known to those skilled in the art
- the coloring agent is a fat-soluble coloring agent or water-soluble.
- Sexual coloring agents such as carotene, cocoa pigment or caramel coloring.
- cyclohexane derivative of the present invention or a stereoisomer or salt thereof is a novel therapeutic drug for anti-neuropsychiatric diseases, has a good clinical application prospect, and brings good news to patients. Social benefits.
- the preparation method of the compound of the invention is simple and easy, and is suitable for industrial production, and has great application value.
- the solid was added to 50 ml of a dichloromethane solution, and 50 ml of a saturated sodium hydrogencarbonate solution was stirred for half an hour, and then the mixture was separated and extracted, and the organic phase was concentrated (0.01 MPa, 40 ° C) to give the object product 3.30 g.
- Composition Dosage (g) Compound 1 (active ingredient) obtained in Example 4 20.0 lactose 126.0 Microcrystalline cellulose 42.0 Hydroxypropylmethylcellulose 4.0 Sodium hydroxyethyl starch 6.0 Magnesium stearate 2.0
- Preparation method the active ingredient, lactose, microcrystalline cellulose and sodium hydroxyethyl starch are mixed, added to a high shear wet granulator, and stirred uniformly at a certain rotation speed; then an aqueous solution of hydroxypropylmethylcellulose is added to the mixture. 50.0 g, suitable pellets were prepared under high shear conditions; then the wet granules were dried by a fluidized bed; the obtained dry granules were uniformly mixed with magnesium stearate and tableted.
- Composition Dosage (g) Compound 1 (active ingredient) obtained in Example 4 50.0 water 3500.0 Polyethylene glycol 50.0 Sorbitol 500.0 Microcrystalline cellulose 25.0 Xanthan gum 5.0 Methylparaben 1.25 Ethyl p-hydroxybenzoate 1.25 Citrate Adjust pH 4 ⁇ 8
- Preparation method methyl p-hydroxybenzoate and ethyl p-hydroxybenzoate are dissolved in hot water, cooled to room temperature (25 ° C ⁇ 2 ° C), and then added sorbitol, polyethylene glycol, xanthan gum, citric acid The salt, the compound 1 having an average particle size of 30 ⁇ m, and the microcrystalline cellulose were uniformly stirred to obtain an oral suspension.
- D 2 receptor cell transfection HEK293 cells were transfected with a plasmid vector containing the D 2 receptor protein gene, and subjected to calcium phosphate transfection, and cultured from the transfected cells through a medium containing G418. As well as the selection of cell monoclonal and radioligand binding experiments, a stable cell line stably expressing the D 2 receptor protein was finally obtained.
- Receptor binding experimental materials isotopic ligand [ 3 H]Spiperone (113.0 Ci/mmol); purchased from Sigma; (+) spiperone, purchased from RBI; GF/B glass fiber filter paper, purchased from Whatman; Tris imported sub-package; PPO, POPOP purchased from Shanghai Reagent No. 1; fat-soluble scintillation liquid. Beckman LS-6500 multi-function liquid scintillation counter.
- Inhibition rate (I%) total binding tube cpm - compound cpm / total binding tube cpm - non-specific binding tube cpm x 100%.
- 5-HT 1A receptor isotope [ 3 H].8-OH-DPAT (purchased from PE), (+) 5-hydroxytrptamine (purchased from Sigma), GF/B glass fiber filter (purchased from Whatman) ), fat-soluble scintillation fluid: PPO, POPOP (purchased from Shanghai Reagent No. 1), toluene (purchased from Sinopharm Chemical Reagent Co., Ltd.), and Tris imported and packaged.
- HEK-293 cells stably expressing 5-HT 1A receptor by gene recombination were cultured in 3-5 cells cultured with DMEM + 10% serum, and cells were harvested with PBS, and the cells were centrifuged at -4 to 3000 rpm. After a minute, discard the supernatant, collect the cells, and store in a -80 degree refrigerator. Resuspend with D 1 Binding Buffer (pH 7.4) during the experiment.
- the competitive inhibition rate of [ 3 H]8-OH-DPAT binding to 5-HT 1A receptor was determined by coarse screening for each compound at a concentration of 10 umol/L.
- Table 1 Compounds for D 2 and D 3 receptor binding assays and nucleophilicity of the 5-HT 1A receptor (Ki: nmol)
- Mode of administration the cyclohexane derivative group of the present invention and the positive control drug cariprazine group are orally administered, MK-801
- the model control group was administered intraperitoneally.
- mice After the mice were administered MK-801, they were immediately placed in a soundproof box, and the total distance of the mouse's voluntary activities in 2.5 hours was observed.
- Table 2 Effect of a single oral administration of a cyclohexane derivative of the invention on the total distance of the open field movement induced by MK-801 in a mouse model of schizophrenia
- the positive control drug kalidazine group significantly inhibited MK-801-induced high spontaneous activity in rats at a dose of 0.3 kg/kg (P ⁇ 0.0001);
- the cyclohexane derivative compounds 1, 2, 3 and 5 of the present invention significantly inhibited MK-801-induced high spontaneous activity in rats at a dose of 0.3 kg/kg (P ⁇ 0.0001), the cyclohexane derivative of the present invention.
- Compounds 6, 7 and 14 also significantly inhibited MK-801-induced high spontaneous activity in rats at a dose of 0.3 kg/kg (P ⁇ 0.05), which was comparable to the positive control drug kalidazine group. Since the MK-801-induced open field exercise model is closely related to the symptoms of schizophrenia, it is indicated that the cyclohexane derivative series of the present invention has a strong anti-schizophrenia symptom.
- the ICR mice were evaluated for oral administration of the compounds of the present invention, and the signs of toxicity and mortality of the animals after oral administration were observed, and the acute toxicity was compared by the Bliss method.
- Observations include, but are not limited to, general conditions, behavioral activities, gait posture, eyes, mouth, nose, gastrointestinal tract, skin coat, genitourinary tract.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
组成成分 | 用量(g) |
实施例4制得的化合物1(活性成分) | 20.0 |
乳糖 | 126.0 |
微晶纤维素 | 42.0 |
羟丙基甲基纤维素 | 4.0 |
羟基乙基淀粉钠 | 6.0 |
硬脂酸镁 | 2.0 |
组成成分 | 用量(g) |
实施例4制得的化合物1(活性成分) | 50.0 |
水 | 3500.0 |
聚乙二醇 | 50.0 |
山梨醇 | 500.0 |
微晶纤维素 | 25.0 |
黄原胶 | 5.0 |
对羟基苯甲酸甲酯 | 1.25 |
对羟基苯甲酸乙酯 | 1.25 |
柠檬酸盐 | 调pH 4~8 |
Claims (13)
- 根据权利要求1或2所述的环己烷衍生物或其立体异构体或盐,其特征在于,所述立体异构体为顺式立体异构体或反式立体异构体,优选为反式立体异构体。
- 根据权利要求1或2所述的环己烷衍生物或其立体异构体或盐,其特征在于,所述环己烷衍生物的盐由环己烷衍生物与酸形成,所述酸为有机酸或无机酸,所述无机酸选自盐酸、硫酸、硝酸或磷酸;所述有机酸选自甲酸、乙酸、草酸丙二酸、马来酸、富马酸、琥珀酸或苯甲酸;以及其他生理学上可以接受的盐。
- 根据权利要求1或2所述的环己烷衍生物或其立体异构体或盐,其特征在于,所述环己烷衍生物或其立体异构体或盐选自以下化合物或其盐:N'-[反式-4-[2-[4-(苯并[b]噻吩)-7-哌嗪基]乙基]环己基]-N,N-二甲基脲,化合物1;N'-[反式-4-[2-[7-(苯并[b]噻吩)-7-哌嗪基]乙基]环己基]-N,N-二甲基脲,化合物2;N'-[反式-4-[2-[4-(苯并[c]噻吩)-7-哌嗪基]乙基]环己基]-N,N-二甲基脲,化合物3;N'-[反式-4-[2-[4-(6-氟-苯并[d]异恶唑)-3-哌嗪基]乙基]环己基]-N,N-二甲基脲,化合物5;N'-[反式-4-[2-[4-(3-氯-苯并[d]异恶唑)-6-哌嗪基]乙基]环己基]-N,N-二甲基脲,化合物6;N'-[反式-4-[2-[4-(6-氟-苯并[d]异恶唑)3-哌啶基]乙基]环己基]-N,N-二甲基脲,化合物7;N'-[反式-4-[2-[4-(苯并[b]噻吩)-7-哌啶基]乙基]环己基]-N,N-二甲基脲,化合物8;N'-[反式-4-[2-[7-(苯并[b]噻吩)-7-哌啶基]乙基]环己基]-N,N-二甲基脲,化合物9;N'-[反式-4-[2-[4-(苯并[C]噻吩)-7-哌啶基]乙基]环己基]-N,N-二甲基脲,化合物10;N'-[反式-4-[2-[4-(苯并[d]异噻唑)-3-哌啶基]乙基]环己基]-N,N-二甲基脲,化合物11;N'-[反式-4-[2-[4-(3-氯-苯并[d]异恶唑)-6-哌啶基]乙基]环己基]-N,N-二甲基脲,化合物12;N'-[反式-4-[2-[4-(3-甲基-苯并[d]异恶唑)-6-哌嗪基]乙基]环己基]-N,N-二甲基脲,化合物13;N'-[反式-4-[2-[4-(6-甲基-苯并[d]异恶唑)-4-哌嗪基]乙基]环己基]-N,N-二甲基脲,化合物14。
- 如权利要求1或2所述环己烷衍生物或其立体异构体或盐的制备方法,其特征在于,所述方法包括下列步骤:4-乙基环己胺衍生物II与N,N-二甲酰基甲酰氯III在缚酸剂存在下反应,得到化合物IB:其中R、X同权利要求1或2所述定义;化合物II与化合物III的摩尔比为1-1.5:1,反应温度为0℃-50℃,缚酸剂为有机碱性物或无机碱性物;所述有机碱性物选自三乙胺、二异丙基乙胺或吡啶中的一种或者几种,所述无机碱性物选自碳酸钠、碳酸钾、碳酸氢钠或碳酸氢钾中的一种或几种,所述缚酸剂与化合物II的摩尔比为1-1.5:1;所述化合物II的制备方法,包括下列步骤:其中R、X如权利要求1或2所述定义,Pg为氨基保护基;(1)当X为氮时,采用哌嗪与溴代物进行偶联反应,得中间体IV;其中所述偶联反应是在钯催化下,强碱性物叔丁醇钾、叔丁醇钠、碳酸钾或碳酸铯的存在下进行,反应温度为50-150℃,哌嗪与溴代物的摩尔比为1-5:1;或当X为C时,中间体IV商业购得;(2)中间体IV与4-氨基保护的环己烷乙醛进行缩合亚胺还原反应,得到中间体V;其中所述还原剂为硼化合物,选自三乙酰氧基硼氢化钠或硼氢化合钠;中间体IV与4-氨基保护的环己烷乙醛的摩尔比为1-1.2:1;硼氢化合物与中间体IV的摩尔比为 1-2:1;(3)脱氨基保护基;当氨基保护基为叔丁氧羰基Boc时,加入酸脱氨基保护基;所述酸为氯化氢有机溶液或三氟乙酸;或当氨基保护基为苄基Bn或甲酸苄酯CBz时,使用钯碳加氢脱氨基保护基,加氢压力为0.1-1Mpa,即得到式II化合物。
- 如权利要求1或2所述的环己烷衍生物或其立体异构体或盐在制备抗神经精神性疾病药物中的应用。
- 根据权利要求7所述的应用,其特征在于,所述应用是指环己烷衍生物或其立体异构体或盐在制备改善/治疗精神分裂、精神紊乱、精神障碍、精神错乱、情绪紊乱、双相类精神障碍、抑郁症、恐惧症、强制性障碍、焦虑症或认知障碍疾病的药物中的应用。
- 根据权利要求7或8所述的应用,其特征在于,所述药物为由式IB或式I所示的环己烷衍生物或其立体异构体或盐作为活性成分与药用辅料组成的药物组合物,所述药物组合物为口服、胃肠道、口腔、舌下、鼻腔、直肠或透皮给药的固体制剂或液体制剂。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES16845713T ES2820842T3 (es) | 2015-09-15 | 2016-09-14 | Derivado de ciclohexano o estereoisómero o sal del mismo, y preparación y uso del mismo |
CA2998758A CA2998758A1 (en) | 2015-09-15 | 2016-09-14 | Cyclohexane derivative or stereoisomer or salt thereof, and preparation and use thereof |
US15/759,119 US10301277B2 (en) | 2015-09-15 | 2016-09-14 | Substituted ureas and methods of treating mental illness using the same |
JP2018532500A JP6772272B2 (ja) | 2015-09-15 | 2016-09-14 | シクロヘキサン誘導体、又はその立体異性体、又はその塩及びその調製と応用 |
EP16845713.3A EP3351540B1 (en) | 2015-09-15 | 2016-09-14 | Cyclohexane derivative or stereoisomer or salt thereof, and preparation and use thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510582267.0 | 2015-09-15 | ||
CN201510582267 | 2015-09-15 | ||
CN201610643389.0 | 2016-08-08 | ||
CN201610643389.0A CN106518841B (zh) | 2015-09-15 | 2016-08-08 | 环己烷衍生物或其立体异构体或盐及其制备与应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017045599A1 true WO2017045599A1 (zh) | 2017-03-23 |
Family
ID=58288064
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2016/098953 WO2017045599A1 (zh) | 2015-09-15 | 2016-09-14 | 环己烷衍生物或其立体异构体或盐及其制备与应用 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2017045599A1 (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020034946A1 (zh) * | 2018-08-14 | 2020-02-20 | 浙江京新药业股份有限公司 | 一种制备环己烷衍生物的方法 |
WO2020034945A1 (zh) * | 2018-08-14 | 2020-02-20 | 浙江京新药业股份有限公司 | 一种环己烷衍生物的制备方法 |
WO2020042903A1 (zh) * | 2018-08-30 | 2020-03-05 | 浙江京新药业股份有限公司 | 一种环己烷衍生物的盐 |
WO2021088920A1 (zh) * | 2019-11-05 | 2021-05-14 | 上海翰森生物医药科技有限公司 | 苯并噻吩类衍生物调节剂、其制备方法和应用 |
CN114634479A (zh) * | 2020-12-16 | 2022-06-17 | 北京盈科瑞创新药物研究有限公司 | 一种派嗪衍生物、其制备方法及应用 |
CN113166135B (zh) * | 2019-11-05 | 2024-10-25 | 上海翰森生物医药科技有限公司 | 苯并噻吩类衍生物调节剂、其制备方法和应用 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101107236A (zh) * | 2005-02-03 | 2008-01-16 | 匈牙利吉瑞大药厂 | 作为多巴胺d3、d2和5ht1a拮抗剂的环己基酰胺 |
CN101511805A (zh) * | 2006-06-22 | 2009-08-19 | 生物计划公司 | 作为多巴胺d3受体配体的新型羰基化(氮杂)环己烷类化合物 |
CN101778844A (zh) * | 2007-07-26 | 2010-07-14 | 弗·哈夫曼-拉罗切有限公司 | 5-ht2a和d3受体的双重调节剂 |
CN102159557A (zh) * | 2008-09-22 | 2011-08-17 | 弗·哈夫曼-拉罗切有限公司 | 哌嗪d3和5-ht2a受体调节剂 |
CN102164914A (zh) * | 2008-09-23 | 2011-08-24 | 弗·哈夫曼-拉罗切有限公司 | 用作多巴胺D3受体调节剂的苯并[d]异*唑-3-基-哌嗪衍生物 |
CN102164927A (zh) * | 2008-09-23 | 2011-08-24 | 弗·哈夫曼-拉罗切有限公司 | 用作多巴胺d3受体调节剂的异唑并[4,5]吡啶-3-基-哌嗪衍生物 |
CN102958936A (zh) * | 2010-07-06 | 2013-03-06 | 霍夫曼-拉罗奇有限公司 | 稠合的吡啶化合物 |
CN103130737A (zh) * | 2011-12-05 | 2013-06-05 | 江苏恒谊药业有限公司 | 环己烷胺类化合物及其作为抗精神分裂症药物的应用 |
CN104140421A (zh) * | 2013-05-08 | 2014-11-12 | 上海医药工业研究院 | 苯并异噻唑类化合物及在制备抗精神分裂症药物中的应用 |
-
2016
- 2016-09-14 WO PCT/CN2016/098953 patent/WO2017045599A1/zh active Application Filing
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101107236A (zh) * | 2005-02-03 | 2008-01-16 | 匈牙利吉瑞大药厂 | 作为多巴胺d3、d2和5ht1a拮抗剂的环己基酰胺 |
CN101511805A (zh) * | 2006-06-22 | 2009-08-19 | 生物计划公司 | 作为多巴胺d3受体配体的新型羰基化(氮杂)环己烷类化合物 |
CN101778844A (zh) * | 2007-07-26 | 2010-07-14 | 弗·哈夫曼-拉罗切有限公司 | 5-ht2a和d3受体的双重调节剂 |
CN102159557A (zh) * | 2008-09-22 | 2011-08-17 | 弗·哈夫曼-拉罗切有限公司 | 哌嗪d3和5-ht2a受体调节剂 |
CN102164914A (zh) * | 2008-09-23 | 2011-08-24 | 弗·哈夫曼-拉罗切有限公司 | 用作多巴胺D3受体调节剂的苯并[d]异*唑-3-基-哌嗪衍生物 |
CN102164927A (zh) * | 2008-09-23 | 2011-08-24 | 弗·哈夫曼-拉罗切有限公司 | 用作多巴胺d3受体调节剂的异唑并[4,5]吡啶-3-基-哌嗪衍生物 |
CN102958936A (zh) * | 2010-07-06 | 2013-03-06 | 霍夫曼-拉罗奇有限公司 | 稠合的吡啶化合物 |
CN103130737A (zh) * | 2011-12-05 | 2013-06-05 | 江苏恒谊药业有限公司 | 环己烷胺类化合物及其作为抗精神分裂症药物的应用 |
CN104140421A (zh) * | 2013-05-08 | 2014-11-12 | 上海医药工业研究院 | 苯并异噻唑类化合物及在制备抗精神分裂症药物中的应用 |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020034946A1 (zh) * | 2018-08-14 | 2020-02-20 | 浙江京新药业股份有限公司 | 一种制备环己烷衍生物的方法 |
WO2020034945A1 (zh) * | 2018-08-14 | 2020-02-20 | 浙江京新药业股份有限公司 | 一种环己烷衍生物的制备方法 |
WO2020042903A1 (zh) * | 2018-08-30 | 2020-03-05 | 浙江京新药业股份有限公司 | 一种环己烷衍生物的盐 |
JP2021535160A (ja) * | 2018-08-30 | 2021-12-16 | 浙江京新薬業股▲ふん▼有限公司Zhejiang Jingxin Pharmaceutical Co., Ltd. | シクロヘキサン誘導体の塩 |
US11584731B2 (en) | 2018-08-30 | 2023-02-21 | Shanghai Jingxin Biology & Pharmaceutical Co., Ltd | Salt of cyclohexane derivative |
WO2021088920A1 (zh) * | 2019-11-05 | 2021-05-14 | 上海翰森生物医药科技有限公司 | 苯并噻吩类衍生物调节剂、其制备方法和应用 |
CN113166135A (zh) * | 2019-11-05 | 2021-07-23 | 上海翰森生物医药科技有限公司 | 苯并噻吩类衍生物调节剂、其制备方法和应用 |
CN113166135B (zh) * | 2019-11-05 | 2024-10-25 | 上海翰森生物医药科技有限公司 | 苯并噻吩类衍生物调节剂、其制备方法和应用 |
CN114634479A (zh) * | 2020-12-16 | 2022-06-17 | 北京盈科瑞创新药物研究有限公司 | 一种派嗪衍生物、其制备方法及应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106518841B (zh) | 环己烷衍生物或其立体异构体或盐及其制备与应用 | |
WO2017045599A1 (zh) | 环己烷衍生物或其立体异构体或盐及其制备与应用 | |
AU685510B2 (en) | Potentiation of drug response | |
US20230201184A1 (en) | Compositions and methods for treating schizophrenia | |
TW200902003A (en) | Quinolone and tetrahydroquinoline and related compounds having NOS inhibitory activity | |
TWI226829B (en) | Pharmaceutical compositions for treatment of partial responders or refractory depression | |
US9550741B2 (en) | Benzoisothiazole compounds and methods of treating schizophrenia | |
TW201002701A (en) | Benzoxazines, benzothiazines, and related compounds having NOS inhibitory activity | |
US6960577B2 (en) | Combination therapy for treatment of refractory depression | |
JP2018510138A (ja) | Olig2活性の阻害 | |
WO2007041936A1 (fr) | Isomeres optiques de derives de piperazine d'alcool d'alkyle et leurs sels ainsi que leurs applications | |
WO2015192672A1 (zh) | 苯并呋喃类衍生物、其制备方法和应用 | |
WO2013152712A1 (zh) | 3-氰基苯胺烷基芳基哌嗪衍生物及其在制备药物中的应用 | |
CN102317261B (zh) | 三重再摄取抑制剂及其应用方法 | |
US8252796B2 (en) | 1-butyl-2-hydroxyaralkyl piperazine derivatives and the uses as anti-depression medicine thereof | |
WO2015007191A1 (zh) | 帕利哌酮氨基酸类衍生物及其应用 | |
CN111285843B (zh) | 新型5-羟色胺和去甲肾上腺素双重再摄取抑制剂及其医药用途 | |
WO2024098856A1 (zh) | 一种抗流感病毒衍生物及其用途 | |
ES2362237T3 (es) | Derivados de 2-(1h-indolilsulfanil)-bencilamina como isrs. | |
TW201026688A (en) | Benzodioxan analogues as alpha2C adrenergic receptor modulators | |
TW200829238A (en) | Dialkylamino alkyl esters of pivagabine as medicaments for the treatment of central nervous system disorders | |
TW317565B (zh) | ||
TW201041581A (en) | N-[(7-azabicyclo[2.2.1]hept-1-yl)-aryl-methyl] benzamide derivatives, preparation thereof and therapeutic use thereof | |
CN116963733A (zh) | 作为enpp1抑制剂的咪唑化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16845713 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15759119 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2018532500 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2998758 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2016845713 Country of ref document: EP |